AKT1 and lung carcinoma: These findings highlight the complex interplay between immune pathways and tumor progression, suggesting that targeting the JAK/STAT3 and PI3K/AKT pathways could be a promising strategy to reduce PD‐L1 expression and enhance antitumor immunity in lung cancer.